Join our daily newsletter At The Bell to receive exclusive market insights
- Paradigm Biopharmaceuticals (PAR) receives a notice of allowance from the US Patent and Trademark Office (USPTO)
- The notification demonstrates PAR’s patent application has been examined and satisfies the requirements for patentability
- The patent refers to a method for improving knee function in a human with bone marrow edema lesions as assessed by MRI and osteoarthritis in a knee using pentosan polysulfate
- Managing Director Paul Rennie says the notice is an excellent outcome for Paradigm as it continues to build the company’s IP portfolio
- Shares in Paradigm are down 3.05 per cent, trading at $1.27 as of 2:05 pm AEDT
Paradigm Biopharmaceuticals (PAR) has received a notice of allowance from the US Patent and Trademark Office (USPTO).
The notification demonstrates the company’s patent application has been examined, and was determined by an examiner to satisfy all requirements for patentability.
Paradigm’s patent referred to a method for improving knee function in a human having bone marrow edema lesions, as assessed by magnetic resonance imaging (MRI) and osteoarthritis in a knee, which is being treated via the administration of pentosan polysulfate.
Managing Director Paul Rennie said the notice is an excellent outcome for Paradigm as it continues to build Paradigm’s IP portfolio across all its indications.
“We are focused on continuing to add additional layers of protection as data becomes available from our preclinical and clinical programs,” Mr Rennie said.
“The Paradigm team continues to further build patent protection around iPPS, a potential blockbuster therapeutic for osteoarthritis.”
In July, the company had completed recruitment for its phase two clinical trial for treating knee OA.
The phase two study aimed to evaluate the treatment of pentosan polysulphate sodium against a placebo on synovial fluid biomarkers in participants with knee osteoarthritis pain.
Shares in Paradigm were down 3.05 per cent, trading at $1.27 as of 2:05 pm AEDT.
